Vandana Singh

PMV Pharmaceuticals Announces Encouraging Early Data from Cancer Study in Pretreated Patients

PMV Pharmaceuticals IncΒ (PMVP) recently provided updated Phase 1 results from its ongoing Phase 1/2 PYNNACLE trial, revealing promising efficacy and favorable safety of its experimental drug, PC14586, in heavily pretreated patients across various tumor types.The data, which were...

Akero Therapeutics' Lead Candidate Potential: Analyst Unpacks Complicated Regulatory Path Forward

Tuesday,Β Akero Therapeutics IncΒ AKRO reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH).Efruxifermin wasΒ notΒ statistically significant in topping the placebo in improving liver scarring without...

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Calidi Biotherapeutics Inc (NYSE: CLDI) is making waves in the biotech industry with its innovative approach to cancer treatment. The company utilizes allogeneic stem cells to deliver oncolytic viruses directly to tumors, offering new hope for patients. Recently, Baird...

Why Novavax’s Delayed COVID Vaccine Approval Aligns with Market Demand

IntroductionNovavax Inc (NASDAQ: NVAX) recently received FDA authorization for its updated COVID-19 vaccine, targeting the omicron subvariant XBB.1.5 in individuals aged 12 and older. While Novavax faced a delay in vaccine release compared to Pfizer Inc (NYSE: PFE)...

Sutro Biopharma’s Luvelta: A Promising Breakthrough in Ovarian Cancer Treatment, Analysts Say

Analysts Predict 200% Upside Potential as Oppenheimer Initiates Coverage on Sutro BiopharmaOppenheimer, a leading financial services firm, has recently initiated coverage on Sutro Biopharma Inc (NASDAQ: STRO) and is predicting remarkable growth for the company, with potential upside...

MaxCyte’s Near-Term Prospects Face Challenges as Revenue Declines, Analysts Express Concerns

Shares of MaxCyte Inc (NASDAQ: MXCT) took a hit as the company reported a decline in preliminary Q3 revenue. The company expects a year-over-year decrease of 25-27%, with Q3 core business revenue down 33-35% Y/Y. This decline in revenue...

BioXcel Faces Funding Challenges as Analyst Downgrades Stock

BioXcel Therapeutics Inc (BTAI) has been downgraded from Buy to Hold by Truist due to significant near-term funding and clinical development challenges. The downgrade comes as the company provides updates on its late-stage clinical programs and patent portfolio...

Promosome Drops Lawsuit Against Pfizer and BioNTech in COVID-19 Vaccine Patent Dispute

Promosome, a biotech firm, has decided to end its lawsuit against Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) regarding patent infringement in messenger RNA technology used in COVID-19 vaccines. While the financial details of the agreement were...

Disney Slashes Ticket Prices for Children as Attendance Slumps

Disney's New Discount for Children Amid Attendance Decline The Walt Disney Company (NYSE: DIS) is implementing discounts for children visiting Disneyland and Disney World parks in an effort to boost attendance. The decline in attendance and hotel occupancy, combined with...

Unlocking Growth Potential: Vivos Therapeutics Strikes Strategic Partnerships to Drive Revenue and Expand Product Line

Introduction Vivos Therapeutics IncΒ (VVOS), a leading sleep disorder therapeutics company, has...